HealthDay News — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update from the U.S. Centers for Disease Control and Prevention ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

As many as 20 people developed a potentially paralysing illness after getting the respiratory syncytial virus (RSV) vaccine.

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...

Australia's flu season has started hard and fast with a significant surge in influenza cases and hospitalisations. Flu deaths ...

The RSV vaccine, given between 32 and 36 weeks of pregnancy, helps expectant mothers pass protective antibodies to their babies—offering critical immunity in the earliest, most vulnerable months ...

Enflonsia joins a short list of new tools to prevent RSV in infants. Another RSV antibody called Beyfortus, made by Sanofi and AstraZeneca, was approved in 2023. But there were supply shortages during ...

The Food and Drug Administration (FDA) has expanded the approval of mResvia (respiratory syncytial virus [RSV] vaccine) to include active immunization in individuals 18 through 59 years of age who ...

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

The vaccine was previously only licensed for adults aged 60 years and older. “RSV poses a serious health risk to adults with certain chronic conditions, and today’s approval marks an important step ...

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.

Moderna's RSV vaccine gets expanded approval for 18-59 year olds at high risk of severe illness, marking a significant step in vaccine protection.